Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Fadraciclib by Cyclacel Pharmaceuticals for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
Fadraciclib by Cyclacel Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
Fadraciclib by Cyclacel Pharmaceuticals for Myelodysplastic Syndrome: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Ovarian Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According...
Fadraciclib by Cyclacel Pharmaceuticals for Cervical Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Endometrial Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Hepatocellular Carcinoma: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Laryngeal Cancer: Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase I for Laryngeal Cancer. According to GlobalData, Phase...
Fadraciclib by Cyclacel Pharmaceuticals for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...